Trusted Rare Disease Intelligence
Connecting clinical data, real-time news, policy tracking, and patient resources across 15,964 rare diseases.
Latest Intelligence
View All NewsHR 7227: Mental Health and MAMA Act of 2026
The Mental Health and MAMA Act of 2026 has been referred to multiple committees for consideration. This legislation aims to address mental health issues, although specific provisions are yet to be detailed.
Epithelioid and spindle cell rhabdomyosarcoma of the rib with FUS-TFCP2 fusion: A case report and literature review.
A case report highlights a rare instance of epithelioid and spindle cell rhabdomyosarcoma of the rib associated with a FUS-TFCP2 fusion. This adds to the understanding of genetic factors in this rare cancer subtype.
Privacy Act of 1974; Matching Program
The Department of Health and Human Services has re-established a matching program between CMS and the Social Security Administration to determine eligibility for Qualified Health Plans. This program aims to streamline the enrollment process and issue certificates of exemption.
Built for the Rare Disease Ecosystem
One platform, four pathways. Find the tools built for your role.
Patients & Families
Understand your rare disease — clearly, completely, in one place.
- Plain-language disease reports
- Patient assistance programs
- Find support organizations
PAG Leaders
Everything your disease community needs — in one place.
- Disease-specific content widgets
- News intelligence for your community
- Newsletter tools & team access
Enterprise & Biotech
Rare disease intelligence via API. 15,964 diseases. Real-time.
- Structured REST API with 18+ endpoints
- AI-generated, QC-validated content
- Deploy in days, not months
Policy Advocates
Track the legislation that affects your patients, across 50 states.
- 50-state policy bill monitoring
- AI-classified by policy category
- Disease-linked legislative tracking
Recently Updated
Browse AllIn the News
All NewsPriovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
Priovant reports positive results from the Phase 2 BEACON study of Brepocitinib for cutaneous sarcoidosis, marking a significant step as the first industry-sponsored placebo-controlled trial in this area. The company is now preparing to advance to Phase 3 trials.
Related Disease Report
sarcoidosis
Sarcoidosis is a multisystemic disorder characterized by the formation of immune granulomas in various organs, though the exact cause remains unknown. The NOD2 gene has been identified in some cases, but the inheritance pattern is not well establishe...
Get Intelligence Delivered
AI-curated rare disease news, delivered weekly. Pipeline approvals, policy changes, funding, and research breakthroughs.
Grounded in open science
Trusted Rare Disease Intelligence
Connecting clinical data, news, policy, and patient resources across 15,964 rare diseases.
Healthcare organization? Learn about our enterprise solutions